These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21072501)

  • 1. Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility.
    Kasten M; Brüggemann N; König IR; Doerry K; Steinlechner S; Wenzel L; Lohmann K; Klein C; Lencer R
    Psychopharmacology (Berl); 2011 Apr; 214(3):729-36. PubMed ID: 21072501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.
    Güzey C; Scordo MG; Spina E; Landsem VM; Spigset O
    Eur J Clin Pharmacol; 2007 Mar; 63(3):233-41. PubMed ID: 17225991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes.
    Gassó P; Mas S; Crescenti A; Alvarez S; Parramon G; Garcia-Rizo C; Parellada E; Bernardo M; Lafuente A
    Psychiatry Res; 2010 Jan; 175(1-2):173-5. PubMed ID: 19892410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.
    Hedenmalm K; Güzey C; Dahl ML; Yue QY; Spigset O
    J Clin Psychopharmacol; 2006 Apr; 26(2):192-7. PubMed ID: 16633151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients.
    Gunes A; Dahl ML; Spina E; Scordo MG
    Eur J Clin Pharmacol; 2008 May; 64(5):477-82. PubMed ID: 18205001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms].
    Kirnichnaya KA; Sosin DN; Ivanov MV; Mikhaylov VA; Ivashchenko DV; Ershov EE; Taraskina AE; Nasyrova RF; Krupitsky EM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(4):113-125. PubMed ID: 26322366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia.
    Muscettola G; Barbato G; Pampallona S; Casiello M; Bollini P
    J Clin Psychopharmacol; 1999 Jun; 19(3):203-8. PubMed ID: 10350026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE).
    Fischer-Barnicol D; Lanquillon S; Haen E; Zofel P; Koch HJ; Dose M; Klein HE;
    Neuropsychobiology; 2008; 57(1-2):80-7. PubMed ID: 18515977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.
    Mas S; Gassó P; Lafuente A; Bioque M; Lobo A; Gonzàlez-Pinto A; Olmeda MS; Corripio I; Llerena A; Cabrera B; Saiz-Ruiz J; Bernardo M;
    Pharmacogenomics J; 2016 Oct; 16(5):439-45. PubMed ID: 27272046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Movement disorders associated with neuroleptic treatment.
    Wirshing WC
    J Clin Psychiatry; 2001; 62 Suppl 21():15-8. PubMed ID: 11584982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.
    Scordo MG; Spina E; Romeo P; Dahl ML; Bertilsson L; Johansson I; Sjöqvist F
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):679-83. PubMed ID: 11214775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased hexosaminidase activity in antipsychotic-induced extrapyramidal side effects: possible association with higher occurrence in bipolar disorder patients.
    Tunca Z; Resmi H; Ozkara HA; Ciliv G; Celtikci B; Alptekin K; Ozerdem A; Akdede BK; Baykara B; Birsoy B; Ergor G
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1214-20. PubMed ID: 18436361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
    Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
    J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis.
    Bernagie C; Danckaerts M; Wampers M; De Hert M
    CNS Drugs; 2016 Sep; 30(9):807-18. PubMed ID: 27395403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS?
    Weiser M; Shneider-Beeri M; Nakash N; Brill N; Bawnik O; Reiss S; Hocherman S; Davidson M
    Schizophr Res; 2000 Dec; 46(2-3):81-9. PubMed ID: 11120419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.
    Miller CH; Mohr F; Umbricht D; Woerner M; Fleischhacker WW; Lieberman JA
    J Clin Psychiatry; 1998 Feb; 59(2):69-75. PubMed ID: 9501888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics.
    Lafuente A; Bernardo M; Mas S; Crescenti A; Aparici M; Gassó P; Catalan R; Mateos JJ; Lomeña F; Parellada E
    Schizophr Res; 2007 Feb; 90(1-3):115-22. PubMed ID: 17150335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
    Honer WG; Kopala LC; Rabinowitz J
    J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway.
    Mas S; Gassó P; Ritter MA; Malagelada C; Bernardo M; Lafuente A
    Eur Neuropsychopharmacol; 2015 Jan; 25(1):51-9. PubMed ID: 25499605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A genetic dissection of antipsychotic induced movement disorders.
    Crisafulli C; Drago A; Sidoti A; Serretti A
    Curr Med Chem; 2013; 20(3):312-30. PubMed ID: 23157623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.